Abstract
HTA143 Drug Market Access Delays in France: What Role May Cost-Effectiveness Evaluations Play in Varying These Timescales?
Full Text
Sign-in/Register to access full text options
Published version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date